✦ LIBER ✦
Preclinical rationale for combined use of endocrine therapy and 5-fluorouracil but neither doxorubicin nor paclitaxel in the treatment of endocrine-responsive breast cancer
✍ Scribed by Junichi Kurebayashi; Mamoru Nukatsuka; Hiroshi Sonoo; Junji Uchida; Mamoru Kiniwa
- Publisher
- Springer
- Year
- 2009
- Tongue
- English
- Weight
- 589 KB
- Volume
- 65
- Category
- Article
- ISSN
- 0344-5704
No coin nor oath required. For personal study only.